Cargando…

Development of sodium fluoride PET response criteria for solid tumours (NAFCIST) in a clinical trial of radium-223 in osteosarcoma: from RECIST to PERCIST to NAFCIST

PURPOSE: The development of osteosarcoma therapeutics has been challenging, in part because of the lack of appropriate criteria to evaluate responses. We developed a novel criteria in a clinical trial of radium-223 dichloride ((223)RaCl(2)) for response assessment in osteosarcoma, NAFCIST (Na(18)F P...

Descripción completa

Detalles Bibliográficos
Autores principales: Kairemo, Kalevi, Rohren, Eric M, Anderson, Pete M, Ravizzini, Gregory, Rao, Arvind, Macapinlac, Homer A, Subbiah, Vivek
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6435244/
https://www.ncbi.nlm.nih.gov/pubmed/30962954
http://dx.doi.org/10.1136/esmoopen-2018-000439
_version_ 1783406622165434368
author Kairemo, Kalevi
Rohren, Eric M
Anderson, Pete M
Ravizzini, Gregory
Rao, Arvind
Macapinlac, Homer A
Subbiah, Vivek
author_facet Kairemo, Kalevi
Rohren, Eric M
Anderson, Pete M
Ravizzini, Gregory
Rao, Arvind
Macapinlac, Homer A
Subbiah, Vivek
author_sort Kairemo, Kalevi
collection PubMed
description PURPOSE: The development of osteosarcoma therapeutics has been challenging, in part because of the lack of appropriate criteria to evaluate responses. We developed a novel criteria in a clinical trial of radium-223 dichloride ((223)RaCl(2)) for response assessment in osteosarcoma, NAFCIST (Na(18)F PET response Criteria in Solid Tumors). EXPERIMENTAL DESIGN: Patients received one to six cycles of (223)RaCl(2), and cumulative doses varied from 6.84 MBq to 57.81 MBq. Molecular imaging with technetium-99m phosphonate scintigraphy, fluorine-18-fluorodeoxyglucose ((18)FDG) positron emission tomography (PET) or sodium fluoride-18 (Na(18)F) PET was used to characterise the disease. Correlation of biomarkers and survival was analysed with NAFCIST measure from Na(18)F PET. RESULTS: Of the 18 patients, 17 had bone lesions visible in at least one of the imaging studies. In four of seven patients with multiple skeletal lesions (>5), FDG PET and NaF PET studies could be compared. The skeletal tumour locations varied in our patient population: cranium=2, extremities=7, pelvis=10, spine=12 and thorax=9. The (18)F-FDG PET and Na(18)F PET studies could be compared in all four patients who had multiple lung lesions (>5). Overall the Response Evaluation Criteria in Solid Tumors response was seen in one patient, but four patients experienced mixed responses better defined by Na(18)F PET. Changes in NAFCIST were correlated with changes in bone alkaline phosphatase levels (r=0.54) and negatively with cumulative dose of (223)RaCl(2) (r=− 0.53). NAFCIST correlated with overall survival (p value of 0.037) while the PERCIST (PET Response Criteria in Solid Tumors) did not (p value of 0.19). CONCLUSIONS: Our results indicate that Na(18)F PET should be further studied in osteosarcoma staging. NAFCIST may be a promising criteria for high-risk osteosarcoma response evaluation and correlates with survival. Further validation studies are needed.
format Online
Article
Text
id pubmed-6435244
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-64352442019-04-08 Development of sodium fluoride PET response criteria for solid tumours (NAFCIST) in a clinical trial of radium-223 in osteosarcoma: from RECIST to PERCIST to NAFCIST Kairemo, Kalevi Rohren, Eric M Anderson, Pete M Ravizzini, Gregory Rao, Arvind Macapinlac, Homer A Subbiah, Vivek ESMO Open Original Research PURPOSE: The development of osteosarcoma therapeutics has been challenging, in part because of the lack of appropriate criteria to evaluate responses. We developed a novel criteria in a clinical trial of radium-223 dichloride ((223)RaCl(2)) for response assessment in osteosarcoma, NAFCIST (Na(18)F PET response Criteria in Solid Tumors). EXPERIMENTAL DESIGN: Patients received one to six cycles of (223)RaCl(2), and cumulative doses varied from 6.84 MBq to 57.81 MBq. Molecular imaging with technetium-99m phosphonate scintigraphy, fluorine-18-fluorodeoxyglucose ((18)FDG) positron emission tomography (PET) or sodium fluoride-18 (Na(18)F) PET was used to characterise the disease. Correlation of biomarkers and survival was analysed with NAFCIST measure from Na(18)F PET. RESULTS: Of the 18 patients, 17 had bone lesions visible in at least one of the imaging studies. In four of seven patients with multiple skeletal lesions (>5), FDG PET and NaF PET studies could be compared. The skeletal tumour locations varied in our patient population: cranium=2, extremities=7, pelvis=10, spine=12 and thorax=9. The (18)F-FDG PET and Na(18)F PET studies could be compared in all four patients who had multiple lung lesions (>5). Overall the Response Evaluation Criteria in Solid Tumors response was seen in one patient, but four patients experienced mixed responses better defined by Na(18)F PET. Changes in NAFCIST were correlated with changes in bone alkaline phosphatase levels (r=0.54) and negatively with cumulative dose of (223)RaCl(2) (r=− 0.53). NAFCIST correlated with overall survival (p value of 0.037) while the PERCIST (PET Response Criteria in Solid Tumors) did not (p value of 0.19). CONCLUSIONS: Our results indicate that Na(18)F PET should be further studied in osteosarcoma staging. NAFCIST may be a promising criteria for high-risk osteosarcoma response evaluation and correlates with survival. Further validation studies are needed. BMJ Publishing Group 2019-02-28 /pmc/articles/PMC6435244/ /pubmed/30962954 http://dx.doi.org/10.1136/esmoopen-2018-000439 Text en © Author (s) (or their employer(s)) 2019. Re-use permitted under CC BY-NC. No commercial re-use. Published by BMJ on behalf of the European Society for Medical Oncology. This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, any changes made are indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.
spellingShingle Original Research
Kairemo, Kalevi
Rohren, Eric M
Anderson, Pete M
Ravizzini, Gregory
Rao, Arvind
Macapinlac, Homer A
Subbiah, Vivek
Development of sodium fluoride PET response criteria for solid tumours (NAFCIST) in a clinical trial of radium-223 in osteosarcoma: from RECIST to PERCIST to NAFCIST
title Development of sodium fluoride PET response criteria for solid tumours (NAFCIST) in a clinical trial of radium-223 in osteosarcoma: from RECIST to PERCIST to NAFCIST
title_full Development of sodium fluoride PET response criteria for solid tumours (NAFCIST) in a clinical trial of radium-223 in osteosarcoma: from RECIST to PERCIST to NAFCIST
title_fullStr Development of sodium fluoride PET response criteria for solid tumours (NAFCIST) in a clinical trial of radium-223 in osteosarcoma: from RECIST to PERCIST to NAFCIST
title_full_unstemmed Development of sodium fluoride PET response criteria for solid tumours (NAFCIST) in a clinical trial of radium-223 in osteosarcoma: from RECIST to PERCIST to NAFCIST
title_short Development of sodium fluoride PET response criteria for solid tumours (NAFCIST) in a clinical trial of radium-223 in osteosarcoma: from RECIST to PERCIST to NAFCIST
title_sort development of sodium fluoride pet response criteria for solid tumours (nafcist) in a clinical trial of radium-223 in osteosarcoma: from recist to percist to nafcist
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6435244/
https://www.ncbi.nlm.nih.gov/pubmed/30962954
http://dx.doi.org/10.1136/esmoopen-2018-000439
work_keys_str_mv AT kairemokalevi developmentofsodiumfluoridepetresponsecriteriaforsolidtumoursnafcistinaclinicaltrialofradium223inosteosarcomafromrecisttopercisttonafcist
AT rohrenericm developmentofsodiumfluoridepetresponsecriteriaforsolidtumoursnafcistinaclinicaltrialofradium223inosteosarcomafromrecisttopercisttonafcist
AT andersonpetem developmentofsodiumfluoridepetresponsecriteriaforsolidtumoursnafcistinaclinicaltrialofradium223inosteosarcomafromrecisttopercisttonafcist
AT ravizzinigregory developmentofsodiumfluoridepetresponsecriteriaforsolidtumoursnafcistinaclinicaltrialofradium223inosteosarcomafromrecisttopercisttonafcist
AT raoarvind developmentofsodiumfluoridepetresponsecriteriaforsolidtumoursnafcistinaclinicaltrialofradium223inosteosarcomafromrecisttopercisttonafcist
AT macapinlachomera developmentofsodiumfluoridepetresponsecriteriaforsolidtumoursnafcistinaclinicaltrialofradium223inosteosarcomafromrecisttopercisttonafcist
AT subbiahvivek developmentofsodiumfluoridepetresponsecriteriaforsolidtumoursnafcistinaclinicaltrialofradium223inosteosarcomafromrecisttopercisttonafcist